Oral vinorelbine and cisplatin with concomitant radiotherapy in stage III non-small cell lung cancer (NSCLC): A feasibility study

Onkologie

Volumn 29, Issue 4, 2006, Pages 137-142

  Beckmann, Gabriele ^a   Fietkau, Rainer ^b   Huber, Rudolf M ^c   Kleine, Philip ^a   Schmidt, Michael ^a   Semrau, Sabine ^b   Aubert, Delphine ^d   Fittipaldo, Alberto ^d   Flentje, Michael ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF ROSTOCK   (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

Chemoradiotherapy; Cisplatin; Consolidation chemotherapy; Non small cell lung cancer; Vinorelbine, oral

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; NAVELBINE;

ADULT; AGED; ANEMIA; ARTICLE; BODY WEIGHT DISORDER; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MEGADOSE; DYSPHAGIA; ESOPHAGITIS; FATIGUE; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GASTRITIS; HUMAN; LEUKOPENIA; LUNG FIBROSIS; LUNG NON SMALL CELL CANCER; MALE; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; RADIATION DOSE; RADIATION INDUCED EMESIS; RADIATION INJURY; RADIATION SICKNESS; THORAX PAIN; THROMBOCYTOPENIA; TREATMENT DURATION; VOMITING; WEIGHT REDUCTION;

EID: 33645658093     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000092062     Document Type: Article

References (23)

1. No authors listed: Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 1995;311:899-909.
2. Marino P, Preatoni A, Cantoni A: Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb non small cell lung cancer. A meta-analysis. Cancer 1995;76:593-601.
3. Pignon JP, Stewart LA: Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb non small cell lung cancer: a meta-analysis. Cancer 1996;77:2413-2414.
4. Pritchard RS, Anthony SP: Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small-cell lung cancer. A meta-analysis. Ann Intern Med 1996;125:723-729.
5. Komaki R, Scott CB, Sause WT, Johnson DH, Taylor SG 4th, Lee JS, Emami B, Byhardt RW, Curran WJ Jr, Dar AR, Cox JD: Induction cisplatin/vinblastine and irradiation vs. irradiation in unresectable squamous cell lung cancer: failure patterns by cell type in RTOG 88-08/ECOG 4588. Radiation Therapy Oncology Group. Eastern Cooperative Oncology Group. Int J Radiat Oncol Biol Phys 1997;39:537-544.
6. Clamon G, Herndon J, Cooper R, Chang AY, Rosenman J, Green MR: Radiosensitization with carboplatin for patients with unresectable stage III non-small-cell lung cancer: a phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group. J Clin Oncol 1999;17:4-11.
7. Komaki R, Seiferheld W, Ettinger D, Lee JS, Movsas B, Sause W: Randomized phase II chemotherapy and radiotherapy trial for patients with locally advanced inoperable non-small-cell lung cancer: long-term follow-up of RTOG 92-04. Int J Radiat Oncol Biol Phys 2002;53:548-557.
8. Huber RM, Flentje M, Gosse H, Poellinger B, Schmidt M, Winner J, Ulm K: Induction chemotherapy and following simultaneous radiochemotherapy versus induction chemotherapy and radiotherapy alone in inoperable NSCLC (Stage IIIA/IIIB): Update of CT/RT 99/97. Proc Am Soc Clin Oncol 2004;22(abstr 7075):14S.
9. Furuse K, Fukuoka M, Kawahara M, Nishikawa H, Takada Y, Kudoh S, Katagami N, Ariyoshi Y: Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999;17:2692-2699.
10. Fournel P, Perol M, Robinet G, Thomas P, Souquet PJ, Hervé L, Vergnenegre A, Delhoume JY, Michel-MontPeyroux F, Mornex F: A randomized phase III trial of sequential chemo-radiotherapy versus concurrent chemo-radiotherapy in locally advanced non small cell lung cancer (NSCLC) (GLOT-GFPC NPC 95-01 study). Proc Am Soc Clin Oncol 2001;20:abstr 1246.
11. Curran WJ, Scott CB, Langer CJ, Komaki R, Lee SJ, Hauser S, Movsas B, Wassermann T, Sause W, Cox JD: Long-term benefit is observed in a phase III comparison of sequential vs concurrent chemoradiation for patients with unresected stage III nsclc: RTOG 9410. Proc Am Soc Clin Oncol 2003;22:abstr 2499.
12. Vokes EE, Herndon JE 2nd, Crawford J, Leopold KA, Perry MC, Miller AA, Green MR: Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431. J Clin Oncol 2002;20:4191-4198.
13. Jassem J, Ramlau R, Karnicka-Mlodkowska H, Krawczyk K, Krzakowski M, Zatloukal P, Lemarie E, Hartmann W, Novakova L, O'Brien M, Depierr A: A multicenter randomized phase II study of oral vs intravenous vinorelbine in advanced non-small cell lung cancer patients. Ann Oncol 2001;12:1375-1381.
14. Bugat R, Variol P, Roche H, Fumoleau P, Robinet G, Senac I: The effects of food on the pharmacokinetic profile of oral vinorelbine. Cancer Chemother Pharmacol 2002;50:285-290.
15. Sause W, Kolesar P, Taylor S IV, Johnson D, Livingston R, Komaki R, Emami B, Curran W Jr, Byhardt R, Dar AR, Turrisi A 3rd: Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 2000;117:358-364.
16. Semrau S, Bier A, Thierbach U, Virchow C, Ketterer P, Fietkau R: Concurrent radiochemotherapy with vinorelbine plus cisplatin or carboplatin in patients with locally advanced non-small-cell lung cancer (NSCLC) and an increased risk of treatment complications. Preliminary results. Strahlenther Onkol 2003;179:823-831.
17. Gralla R, Harper P, Johnson S, Delgado FM: Vinorelbine (Navelbine®) in the treatment of non-small cell lung cancer: studies with single-agent therapy and in combination with cisplatin. Ann Oncol 1999;10(suppl 5):S41-S45.
18. Gridelli C, Guida C, Barletta E, Gatani T, Fiore F, Barzelloni ML, Rossi A, de Bellis M, D'Aniello R, Scognamiglio F: Thoracic radiotherapy and daily vinorelbine as radiosensitizer in locally advanced non small cell lung cancer: a phase I study. Lung Cancer 2000;29:131-137.
19. Marty M, Fumoleau P, Adenis A, Rousseau Y, Merrouche Y, Robinet G, Senac I, Puozzo C: Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors. Ann Oncol 2001;12:1643-1649.
20. Nguyen L, Tranchand B, Puozzo C, Variol P: Population pharmacokinetics model and limited sampling strategy for intravenous Vinorelbine derived from phase I clinical trials. Br J Clin Pharmacol 2002:459-468.
21. Gaspar LE, Chansky K, Albain KS, Vallieres E, Rusch V, Crowley JJ, Livingston RB, Gandara DR: Time from treatment to subsequent diagnosis of brain metastases in stage III non-small-cell lung cancer: a retrospective review by the Southwest Oncology Group. J Clin Oncol 2005;23:2955-2961.
22. Mamon HJ, Yeap BY, Janne PA, Reblando J, Shrager S, Jaklitsch MT, Mentzer S, Lukanich JM, Sugarbaker DJ, Baldini EH, Berman S, Skarin A, Bueno R: High risk of brain metastases in surgically staged IIIA non-small-cell lung cancer patients treated with surgery, chemotherapy, and radiation. J Clin Oncol 2005;23:1530-1537.
23. Lester JF, Macbeth FR, Coles B. Prophylactic cranial irradiation for preventing brain metastases in patients undergoing radical treatment for non-small-cell lung cancer: A cochrane review. Int J Radiat Oncol Biol Phys 2005;63:690-694.